320 related articles for article (PubMed ID: 36527456)
1. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
Sun Y; Yue L; Hu W
Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
[TBL] [Abstract][Full Text] [Related]
3. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
Dong SQ; Singh TP; Wei X; Yao H; Wang HL
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
[TBL] [Abstract][Full Text] [Related]
4. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
Liu L; Shi H; Shi Y; Wang A; Guo N; Li F; Nahata MC
Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
[TBL] [Abstract][Full Text] [Related]
6. Treatment of
Kanu JE; Soldera J
World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Kajihara Y; Shimoyama T; Mizuki I
Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
Jung YS; Kim EH; Park CH
Aliment Pharmacol Ther; 2017 Jul; 46(2):106-114. PubMed ID: 28497487
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
[No Abstract] [Full Text] [Related]
12. Vonoprazan-amoxicillin dual therapy for
Zhou BG; Mei YZ; Jiang X; Zheng AJ; Ding YB
Saudi J Gastroenterol; 2023; 29(6):347-357. PubMed ID: 37602635
[TBL] [Abstract][Full Text] [Related]
13. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
[TBL] [Abstract][Full Text] [Related]
14. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of
Liu L; Nahata MC
Ann Pharmacother; 2023 Oct; 57(10):1185-1197. PubMed ID: 36688309
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan: A Review in Helicobacter pylori Infection.
Shirley M
Drugs; 2024 Mar; 84(3):319-327. PubMed ID: 38388872
[TBL] [Abstract][Full Text] [Related]
16. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
[TBL] [Abstract][Full Text] [Related]
18. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
[TBL] [Abstract][Full Text] [Related]
19. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
Sue S; Maeda S
Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058
[TBL] [Abstract][Full Text] [Related]
20. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
